Profil bibliographique

Hiroki Ishihara

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

318Publications signalées

2644Citations signalées

1Affiliations récentes

Les institutions déclarées

Tokyo Women's Medical University

Les domaines associés

Renal cell carcinoma treatmentCancer Immunotherapy and BiomarkersBladder and Urothelial Cancer TreatmentsMultiple and Secondary Primary CancersFerroptosis and cancer prognosis

Les publications récentes

2026 article OpenAlex

Effectiveness and Safety of Enfortumab Vedotin Plus Pembrolizumab for Patients Aged 80 Years and Older With Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study

Yuki Kobari, Nao Nakajima, AKIRA SAITO, Nanaka Katsurayama et autres

jp (code pays fourni par la source)

0 citations Anticancer Research

Accès ouvert 2026 preprint OpenAlex

Impact of body mass index on the clinical outcomes of immune checkpoint inhibitor combination therapy for advanced renal cell carcinoma: insights from gene expression and tumor-infiltrating immune cell profile

Hiroki Ishihara, Hironori Fukuda, Akihiro Kumono, Yuki Nemoto et autres

jp, gb (code pays fourni par la source)

0 citations Research Square

Accès ouvert 2026 other OpenAlex

Table S8 from Non–Clear Cell Renal Cell Carcinoma Has an Immune-Cold Phenotype That Affects Response to Immune Checkpoint Inhibitors

Hiroki Ishihara, Yuyu Liu, Riu Yamashita, Hironori Fukuda et autres

0 citations

Accès ouvert 2026 other OpenAlex

Table S9 from Non–Clear Cell Renal Cell Carcinoma Has an Immune-Cold Phenotype That Affects Response to Immune Checkpoint Inhibitors

Hiroki Ishihara, Yuyu Liu, Riu Yamashita, Hironori Fukuda et autres

0 citations

Accès ouvert 2026 other OpenAlex

Table S7 from Non–Clear Cell Renal Cell Carcinoma Has an Immune-Cold Phenotype That Affects Response to Immune Checkpoint Inhibitors

Hiroki Ishihara, Yuyu Liu, Riu Yamashita, Hironori Fukuda et autres

0 citations

Accès ouvert 2026 other OpenAlex

Table S10 from Non–Clear Cell Renal Cell Carcinoma Has an Immune-Cold Phenotype That Affects Response to Immune Checkpoint Inhibitors

Hiroki Ishihara, Yuyu Liu, Riu Yamashita, Hironori Fukuda et autres

0 citations

Accès ouvert 2026 other OpenAlex

Figure S3 from Non–Clear Cell Renal Cell Carcinoma Has an Immune-Cold Phenotype That Affects Response to Immune Checkpoint Inhibitors

Hiroki Ishihara, Yuyu Liu, Riu Yamashita, Hironori Fukuda et autres

0 citations

Accès ouvert 2026 other OpenAlex

Table S5 from Non–Clear Cell Renal Cell Carcinoma Has an Immune-Cold Phenotype That Affects Response to Immune Checkpoint Inhibitors

Hiroki Ishihara, Yuyu Liu, Riu Yamashita, Hironori Fukuda et autres

0 citations

Accès ouvert 2026 other OpenAlex

Figure S1 from Non–Clear Cell Renal Cell Carcinoma Has an Immune-Cold Phenotype That Affects Response to Immune Checkpoint Inhibitors

Hiroki Ishihara, Yuyu Liu, Riu Yamashita, Hironori Fukuda et autres

0 citations

Accès ouvert 2026 other OpenAlex

Figure S7 from Non–Clear Cell Renal Cell Carcinoma Has an Immune-Cold Phenotype That Affects Response to Immune Checkpoint Inhibitors

Hiroki Ishihara, Yuyu Liu, Riu Yamashita, Hironori Fukuda et autres

0 citations

Accès ouvert 2026 other OpenAlex

Figure S5 from Non–Clear Cell Renal Cell Carcinoma Has an Immune-Cold Phenotype That Affects Response to Immune Checkpoint Inhibitors

Hiroki Ishihara, Yuyu Liu, Riu Yamashita, Hironori Fukuda et autres

0 citations

Accès ouvert 2026 other OpenAlex

Table S11 from Non–Clear Cell Renal Cell Carcinoma Has an Immune-Cold Phenotype That Affects Response to Immune Checkpoint Inhibitors

Hiroki Ishihara, Yuyu Liu, Riu Yamashita, Hironori Fukuda et autres

0 citations

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.